Biocompatibility of surgical-grade dense polycrystalline alumina.

This article reviews the knowledge about biocompatibility of alumina since its introduction as a material for use in joint replacements. Alumina is a hydrophilic material with high wettability allowing very low friction with negligible wear. Macrophages loaded with alumina particles show no morphologic alteration and do not lose their chemotactic ability. The host response has been studied for bulk and particulate alumina in soft tissues, as well as in human and animal bone under loaded and nonloaded conditions. The soft-tissue response to bulk alumina exhibits minimal fibrosis, and direct bone contact is achieved at compression-loaded interfaces. Examination of human biopsies from failed total hip prostheses reveals a foreign-body reaction containing predominantly macrophages loaded with alumina particles. No lymphocyte or plasma-cell infiltration is observed because of the absence of soluble component release. The amount of necrosis and fibrosis was lower than that associated with metal or polyethylene debris. In summary, alumina exhibits greater bioinertness than all other implant materials currently available for joint replacement.     

Probleme bei gynäkologischen Endoskopien aus der Sicht der Gynäkologie und Anästhesiologie

Zum Thema Die Endoskopie hat in der operativen Gyn?kologie in den letzten Jahren zunehmend an Bedeutung gewonnen. Neben ihrem Einsatz in der Diagnostik werden auch operativ-therapeutische Eingriffe immer h?ufiger endoskopisch vorgenommen. In vielen F?llen kann dadurch eine Laparotomie mit ihren Risiken und postoperativen Problemen und der damit verbundenen l?ngeren postoperativen Hospitalisation vermieden werden. Auch bei endoskopischen Eingriffen k?nnen schwerwiegende operative Komplikationen auftreten wie z. B. Blutungen oder Verletzungen von Nachbarorganen wie Darm, Blase, Ureter, Magen [8, 16, 17, 21]. Darüber hinaus kommt es durch die Anlage des Pneumoperitoneums und die Lagerung der Patientinnen bei der Laparoskopie und durch den Einsatz von Spüll?sungen bei der operativen Hysteroskopie zu pathophysiologischen Ver?nderungen, deren Kenntnis für Operateur und An?sthesist zur Vermeidung von Komplikationen unabdingbar ist [18, 25].     

Evidence for a discrete binding protein of plasminogen activator inhibitor in plasma

Gel-filtration experiments of mixtures of functionally active and inactive forms of plasminogen activator inhibitor (PAI) with human plasma or bovine serum albumin have provided evidence for the existence of a discrete binding protein of PAI in plasma. Most likely it is a glycoprotein with a molecular weight of approximately 150,000. The data suggest that it forms a very stable complex with functionally active forms of PAI, but not with the inactive or "latent" PAI. However, the PAI activity seems not to be significantly altered by the interaction with the binding protein. Assuming that a stoichiometric complex is formed, titration experiments suggest that a pool of normal human plasma contains about 40-50 mg of PAI-binding protein liter.     

Sweden: growing interest in ethics

Lindahl's bibliographic essay highlights five books, two doctoral theses, and several journal articles that are Sweden's major contributions to the bioethics literature. The books are H. Fagerberg's edited work on medical ethics (1984), widely used as a textbook in Sweden's medical and nursing schools; G. Wretmark, A. Wretmark, and J. Ludvigsson's co-authored text on ethics in medical care (1983); physician A. Andrén-Sandberg's case book (1986); theologian B. Hanson's collection of essays (1988); and Fagerberg's edited work on the ethics of prenatal diagnosis (1980). The theses are C. Blomquist's (1971), the first in Sweden on medical ethics, and C. Kjellstrand's 1988 work on high technology medicine. The articles include two on medical ethics in Sweden written by Lindahl and published in issues of Theoretical Medicine, the only cited works in English.     

Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection

Intranasal immunization of mice with Rib, a cell surface protein of group B streptococcus (GBS), conjugated to or simply coadministered with the recombinant cholera toxin B subunit, induces systemic immunoglobulin G (IgG) and local IgA antibody responses and confers protection against lethal GBS infection. These findings have implications for the development of a human GBS vaccine.     

High prevalence of hepatitis C virus type 5 in central France evidenced by a prospective study from 1996 to 2002

From 1996 to 2002, hepatitis C virus (HCV) typing was prospectively performed for 1,281 unselected HCV-infected and viremic patients, irrespective of their clinical status. Eighty-three patients (6.5%) were coinfected with human immunodeficiency virus (HIV) and HCV. A total of 1,195 strains were identified by a serotype screening (Murex HCV Serotyping 1-6 assay) and/or genotyping (Inno-LiPA HCV II) test. The distribution of HCV types showed an unusually high rate of type 5 (14.2%) that was stable over time and was the third most frequent type, after type 1 (59.1%) and type 3 (15.1%). HCV type 5 was more frequent in patients who were older than 50 (P = 10(-6)), but its frequency did not differ significantly by gender (P = 0.21). Serotyping was performed for 1,160 strains but failed for 30.2% of them. The efficiency depended on HIV status (for HCV-HIV-coinfected patients, half of the strains were untypeable) and HCV type. Genotyping was performed for 428 samples, with an overall efficiency of 99.3%. It failed in three cases, which were subsequently identified as HCV type 2. Serotyping and genotyping results for 39 patients showed discrepancies between the two methods for 4 patients, who had HCV type 2, type 6, or mixed infections. Thus, HCV type 5 may also be encountered frequently in Western countries. Its apparent confinement to a restricted area raises the question of how it emerged and underscores the need for further studies of HCV type prevalence, routes of transmission, pathogenicity, and responses to treatment.     

Characterization of an IgA receptor from group B streptococci: specificity for serum IgA

Some strains of group B streptococci express a cell surface protein which binds IgA. This report describes some properties of such an IgA receptor and compares it with a previously described IgA receptor from group A streptococci. The group B receptor was released in an almost pure form from bacteria incubated at elevated pH, and could be isolated by IgA-Sepharose affinity chromatography. The sequence of the N-terminal 19 amino acid residues was unique. The receptor preferentially binds IgA of human origin, as shown in immunoblotting experiments with purified IgA from nine different species. The affinity constant of the purified receptor for serum IgA was determined to be 3.5 x 10(8) M-1, but for secretory IgA it was too low to allow determination. This result indicates that secretory component and/or J chain interferes with the binding of IgA to this type of bacterial receptor, which may be one of the physiological functions of these polypeptides. A reduction in affinity was also observed for another complexed form of IgA, alpha 1-microglobulin-IgA. The group B receptor is antigenically unrelated to the IgA receptor from group A streptococci (protein Arp), but competitive inhibition experiments indicate that they bind to the same region in IgA. The implications of these findings, and the biological role of bacterial IgA receptors, are discussed.     

A monoclonal antibody against a new differentiation antigen of thymocytes

B14-2-14 is a monoclonal cytotoxic IgM antibody which reacts with thymocytes of all mouse strains tested. The fraction of positive cells (by visual immunofluorescence) varies between strains from about 25-45% in A.CA to 65-85% in C57BL/6, and high levels are dominant in F1 hybrids. In the periphery, the antigen is found on a few percent of lymph node and not on splenic T cells, and it is absent in nude mice. Among thymocytes, the distribution of the B14 determinant largely overlaps with that of the TL antigen and of molecules binding peanut agglutinin. The B14 antibody reacts only minimally with hydrocortisone-resistant thymus cells. Biochemical analysis shows that B14 antibody, anti-TL antibody and peanut agglutinin bind to separate molecules. The target of the B14 antibody may be either an immature, thymic form of Thy-1, or another molecule associated with it. Two polypeptides, of 40 and 35 kDa are precipitated by both B14 and anti-Thy-1 antibodies from biosynthetically labeled thymus cell lysates, and two others, of 27 and 17 kDa, from surface-iodinated thymus cell preparations. B14-2-14 offers an additional method for identification and selection of thymocytes at different stages of differentiation, and should also be useful for studies of the Thy-1 antigen.